Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Shire Appoints Susan Kilsby as Its New Chairman Effective April 2014



Shire has reported that Matthew Emmens will retire as non-executive chairman and Susan Kilsby, chairman of Shire’s Audit, Compliance & Risk Committee, will succeed him after the conclusion of Shire’s AGM on April 29, 2014. Emmens joined the company as chief executive in 2003 and became chairman of Shire in 2008. Kilsby joined the Shire Board as a non-executive director in September 2011. In May 2013, she was appointed chairman of Shire’s Audit, Compliance & Risk Committee. Dominic Blakemore will replace Kilsby’s position as chairman of Shire’s Audit, Compliance & Risk Committee. In addition, Kilsby’s will become a member of Shire’s Nomination Committee, effective February 1, 2014.

Source: Shire

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here